Tuesday - July 1, 2025
New Data Show TREMFYA (guselkumab) is the Only IL-23 Inhibitor Proven to Significantly Inhibit Progression of Joint Structural Damage in Active Psoriatic Arthritis
June 12, 2025
RARITAN, New Jersey, June 12 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

New data show TREMFYA (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

TREMFYA demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in th . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products